Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]
Overall survival results from a study with a combination of [...]
A recent phase II clinical trial has shown that combined [...]
Results from this trial for papillary renal cell carcinoma (RCC) [...]